BRAX.F Stock Overview
Operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Braxia Scientific Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0024 |
| 52 Week High | CA$0.012 |
| 52 Week Low | CA$0.0013 |
| Beta | 1.25 |
| 11 Month Change | 2.08% |
| 3 Month Change | -51.00% |
| 1 Year Change | -75.50% |
| 33 Year Change | -98.40% |
| 5 Year Change | n/a |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRAX.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 6.5% | 0.2% | 0.9% |
| 1Y | -75.5% | 12.2% | 32.4% |
Return vs Industry: BRAX.F underperformed the US Healthcare industry which returned 9.7% over the past year.
Return vs Market: BRAX.F underperformed the US Market which returned 32.1% over the past year.
Price Volatility
| BRAX.F volatility | |
|---|---|
| BRAX.F Average Weekly Movement | 40.0% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BRAX.F's share price has been volatile over the past 3 months.
Volatility Over Time: BRAX.F's weekly volatility has increased from 27% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Roger McIntyre | braxiascientific.com |
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform.
Braxia Scientific Corp. Fundamentals Summary
| BRAX.F fundamental statistics | |
|---|---|
| Market cap | US$1.05m |
| Earnings (TTM) | -US$7.13m |
| Revenue (TTM) | US$1.63m |
0.6x
P/S Ratio-0.1x
P/E RatioIs BRAX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRAX.F income statement (TTM) | |
|---|---|
| Revenue | CA$2.21m |
| Cost of Revenue | CA$1.89m |
| Gross Profit | CA$324.11k |
| Other Expenses | CA$9.96m |
| Earnings | -CA$9.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 14.67% |
| Net Profit Margin | -436.37% |
| Debt/Equity Ratio | -29.6% |
How did BRAX.F perform over the long term?
See historical performance and comparison